With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

and Logos Capital, as well as existing investors. Goldman Sachs’ life sciences managing director Colin Walsh has joined Attovia’s board. Goldman Sachs also led a $95 million third-round ...